Posted by Michael Wonder on 01 May 2019
PHARMAC fully funding innovative improvements in haemophilia treatment
30 April 2019 - PHARMAC has today provided haemophilia patients fully funded access to new innovative treatment options which will make a major difference to their lives, PHARMAC Director of Operations Lisa Williams says.
“PHARMAC now funds two innovative, highly effective, longer-acting treatments that mean people with haemophilia will need fewer injections to maintain active lives and prevent bleeding episodes that can result in long-term disability.
“People with haemophilia in New Zealand will now have some of the broadest access in the world to the new longer-acting treatments.
